The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Navtemadlin and its role in the treatment of R/R myelofibrosis
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some updates on navtemadlin, an MDM2 inhibitor, for the treatment of myelofibrosis (MF). Dr Verstovsek first highlights the potential role of nevtemadlin in relapsed/refractory (R/R) disease, and then goes on to discuss the Phase III BOREAS study (NCT03662126), which is evaluating the use of this agent versus best available therapy in patients with MF who progress after JAK inhibitor therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
